Isatuximab for anemia, aplastic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Jun 2026: Trial started, NCT07714512
  2. 20 Jul 2026: Trial registered, NCT07714512

The trials

NCT07714512: Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia

State
Under way
Phase
Phase 1 and Phase 2
People
32 planned
Started
30 Jun 2026
Primary completion
30 Jun 2028
Arms
Isatuximab
Results
None posted
  1. 30 Jun 2026: Trial started
  2. 20 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.